EGFR exon 20 insertion variants A763_Y764insFQEA and D770delinsGY confer favorable sensitivity to currently approved EGFR-specific tyrosine kinase inhibitors

Guangjian Yang1†, Yaning Yang2†, Jiaqi Hu3, Haiyan Xu4, Shuyang Zhang2 and Yan Wang2*  

1Department of Respiratory Medicine, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China, 2Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 3Drug Discovery Business Unit, PharmaBlock Sciences (Nanjing), Inc, Nanjing, Jiangsu, China, 4Department of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Background: The EGFR exon 20 insertions (ex20ins) D770_N771insSVD and V769_D770insASV are most frequent in non-small-cell lung cancer (NSCLC) and are associated with intrinsic resistance to currently approved EGFR tyrosine kinase inhibitors (TKIs). A763_Y764insFQEA and D770delinsGY, respectively, account for 3%–8% and 2.0%–4.8% of EGFR ex20ins in NSCLC and are associated with a more favorable response to EGFR-specific TKIs as per case reports. The aim of this study was to elucidate the molecular structures of these mutants and their binding affinities to diverse EGFR TKIs and compare the clinical outcomes in NSCLC patients harboring these mutations.

Methods: A real-world cohort study was conducted to evaluate and compare the clinical outcomes of EGFR TKIs among NSCLC patients with different EGFR ex20ins mutants in response to EGFR TKIs. The structures of A763_Y764insFQEA and D770delinsGY were also analyzed and drug binding simulations were performed.

Results: With a median follow-up of 24.0 months, the first-line objective response rate (ORR), disease control rate (DCR), and median progression-free survival (PFS) were, respectively, 0 (0/16), 50.0% (8/16), and 2.07 months.
(95%CI, 0.002–0.013 nM to 2nd-gen EGFR TKIs) (Lee et al., 2019). In addition, another unique insertion D770delinsGY also sensitizes NSCLC cell lines and patients to 2nd- or 3rd-gen EGFR TKIs (Jänne et al., 2011; Kosaka et al., 2017; Yang et al., 2020; Yang J et al., 2021). Codon Asp770 (D770) is located in the pivot point of the EGFR C-helix, and the replacement of D770 with the inserted glycine potentially restores the wild-

**Conclusion:** NSCLC patients harboring A763_Y764insFQEA and D770delinsGY insertions of EGFR are responsive to the currently approved EGFR TKIs as opposed to patients with the D770_N771insSVD and V769_D770insASV variants. Therefore, A763_Y764insFQEA and D770delinsGY should be classified as active mutations among heterogeneous EGFR ex20ins subtypes and the carriers can be treated with the suitable EGFR TKIs.

**KEYWORDS**

EGFR, exon 20 insertion, A763_Y764insFQEA, D770delinsGY, tyrosine kinase inhibitor, D770_N771insSVD, V769_D770insASV

---

**Introduction**

Exon 19 deletions and the L858R substitution in exon 21 are the most frequent epidermal growth factor receptor (EGFR)-activating mutations in non-small-cell lung cancer (NSCLC) and are associated with the sensitivity to EGFR tyrosine kinase inhibitors (TKIs), including the first-generation (1st-gen) gefitinib and erlotinib, second-generation (2nd-gen) afatinib and dacomitinib, and third-generation (3rd-gen) osimertinib (Mok et al., 2009; Soria et al., 2018). In addition, other less common EGFR mutations (e.g., G719X, S768I, and L861Q) correlate variably with the sensitivity to EGFR TKIs and with a favorable response to 2nd-gen TKI afatinib (Yang et al., 2015). Generally, TKIs are the preferred treatment for NSCLC patients harboring these EGFR mutations.

The prevalence of EGFR-activating exon 20 insertions (ex20ins) is only 4%–10% in NSCLC patients (Yasuda et al., 2012; Arcila et al., 2013; Oxnard et al., 2013). The elucidation of the crystal structure of the insertion mutant D770_N771insNPG provided the first insights into the mechanism of EGFR activation and ex20ins-mediated resistance to EGFR inhibitors (Yasuda et al., 2013). Subsequent structural and in vitro kinetic studies confirmed that ex20ins can lock the EGFR kinase in an active state in the absence of ligand binding as opposed to the other EGFR mutations (Yasuda et al., 2013; Robichaux et al., 2018). The vast majority of ex20ins are located in the phosphate-binding loop (P-loop) region following the C-helix, which is the determinant of EGFR kinase activity (Eck and Yun, 2010; Vyse and Huang, 2019). In addition, nearly all the ex20ins of EGFR exhibit significant steric hindrance and a lack of affinity for the currently approved 1st-to-3rd-gen EGFR-specific TKIs, which can be attributed to the prominent shift of the C-helix and P-loop into the drug-binding pocket of EGFR (Wu et al., 2008; Yasuda et al., 2012; Yasuda et al., 2013; Robichaux et al., 2018; Yang et al., 2020).

Among these heterogeneous ex20ins variants, A763_Y764insFQEA has an insertion within the middle of the C-helix and shows high affinity to diverse EGFR TKIs reported according to both in vitro and clinical studies (Arcila et al., 2013; Voon et al., 2013; Yasuda et al., 2013; Hasegawa et al., 2019; Yang et al., 2020; Yang G et al., 2021). NSCLC cells expressing the D770_N771insSVD and V769_D770insASV mutants are resistant to both 1st-gen (IC50, 3479.3-5179.7 nM) and 2nd-gen (IC50, 54.1-85.9 nM) EGFR TKIs as opposed to those expressing the A763_Y764insFQEA variant (IC50, 21.7-33.3 nM to 1st-gen EGFR TKIs; 0.002–0.013 nM to 2nd-gen EGFR TKIs) or the wild-type EGFR (IC50, 3479.3-5179.7 nM) and 2nd-gen (IC50, 54.1-85.9 nM) EGFR TKIs as opposed to those expressing the A763_Y764insFQEA variant (IC50, 21.7-33.3 nM to 1st-gen EGFR TKIs; 0.002–0.013 nM to 2nd-gen EGFR TKIs) or the wild-type EGFR (IC50, 1127-1333.1 nM to 1st-gen EGFR TKIs; 7.3-39 nM to 2nd-gen EGFR TKIs) (Lee et al., 2019). In addition, another unique insertion D770delinsGY also sensitizes NSCLC cell lines and patients to 2nd- or 3rd-gen EGFR TKIs (Jänne et al., 2011; Kosaka et al., 2017; Yang et al., 2020; Yang J et al., 2021). Codon Asp770 (D770) is located in the pivot point of the EGFR C-helix, and the replacement of D770 with the inserted glycine potentially restores the wild-
type C-helix conformational changes and the affinity for TKIs (Kosaka et al., 2017). Given the low frequency of A763_Y764insFQEA (3%-8%) (Riess et al., 2018; Yang et al., 2020; Yang G et al., 2021; Geng et al., 2022) and D770delinsGY (2.0%-4.8%) (Yang et al., 2020; Yang J et al., 2021) variants, their response to diverse EGFR TKIs in the real world NSCLC cohorts is ambiguous. In addition, their structures and binding affinity to EGFR TKIs have also not been ascertained. This highlights the need for further studies to understand the underlying mechanisms underlying the favorable response of NSCLC patients harboring these two specific insertion variants of EGFR to EGFR TKIs. Therefore, we conducted a real-world study to investigate the targeted outcomes of diverse EGFR TKIs in NSCLC patients with the A763_Y764insFQEA and D770delinsGY variants, and compared them with the therapeutic response in patients harboring other EGFR ex20ins subtypes. Furthermore, we also constructed the three-dimensional (3D) structures of A763_Y764insFQEA and D770delinsGY to simulate and predict their binding affinity to EGFR TKIs.

Patients and methods

Patients

This study retrospectively collected medical data of metastatic NSCLC patients with EGFR ex20ins at the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences between 10 May 2016, and 10 September 2021. The inclusion criteria were as follows: 1) stage IV disease at initial diagnosis; 2) ≥18 years of age; 3) histologically or cytologically confirmed NSCLC; 4) EGFR ex20ins mutations confirmed at initial diagnosis by next-generation sequencing (NGS) testing with formalin-fixed, paraffin-embedded tissue samples or liquid biopsy samples; and 5) documented treatment with EGFR TKIs in the first- or second-line setting. The NGS testing in this study was performed in institutional laboratories or qualified third-party genetic testing companies as documented in medical records, which had acquired the national quality system certification in China, and all of the NGS tests were carried out based on the Illumina sequencing system. All clinical data were extracted from electronic records. As a retrospective observational study, informed consent was exempted. The study was approved by the Ethics Committee of the National Cancer Center and conducted in accordance with the Declaration of Helsinki.

Treatment and assessment

Eligible patients were included in molecular and efficacy analysis. Patients treated with EGFR TKIs were at a standard dose according to clinical guidelines in practice. Baseline images of measurable target lesions were obtained with computed tomography of the chest and abdomen, and magnetic resonance imaging of the brain. Guideline from the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) was performed to identify a response of complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). The targeted response was evaluated by investigators involved in this study and had been double-checked according to the medical images provided by patients. Progression-free survival (PFS) was defined as the time from initiation of EGFR TKIs to the date of documented disease progression or death from any cause. The objective response rate (ORR) was calculated as the percentage of confirmed CR and PR. Disease control rate (DCR) was defined as the percentage of CR, PR, and SD.

Molecular dynamics simulation

The 3D-modeling of A763_Y764insFQEA and D770delinsGY mutants were computationally constructed based on the crystal structure of the wild-type (WT) EGFR kinase domain using the Schrödinger software (2020-1 Release) (PDB: 4I23). The protein was prepared using Maestro software (Schrödinger 2021-1 Release) in the Schrödinger modeling package. Compounds of afatinib, dacomitinib, osimertinib, poziotinib, mobocertinib (TAK-788), and CLN-081 (TAS6417) were constructed using the 3D-sketcher module in Maestro. For the prediction of bioactive conformation and binding modes with the abovementioned compounds, we conducted docking simulations using the GLIDE (Schrödinger 2020-1 Release) program from Schrödinger Inc. (Portland, Oregon). The computer-based binding free energy ($\Delta G_{\text{bind}}$) was calculated with the GlideScore method and the Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) method. Figures were produced by Molecular Operating Environment software (MOE 2021.01 Chemical Computing Group, Montreal, Canada). The detailed content regarding $\Delta G_{\text{bind}}$ of a protein–ligand complex is listed in the Supplementary Appendix.

Statistical analysis

Statistical analyses were conducted using SPSS version 23.0 (SPSS Inc., Chicago, IL, United States). Continuous variables were summarized using medians and ranges, and categorical variables were described using frequency and percentage. Comparison among the subgroups was performed using analysis of variance or Chi-Square test accordingly. PFS and OS were analyzed using the Kaplan–Meier method. PFS between different subgroups were compared using a log-rank test (two-
TABLE 1 Clinicopathological characteristics of NSCLC patients with EGFR exon 20 insertions treated with first-line targeted therapy.

| Characteristics | FQEA/GY (n = 13) | Others (n = 11) | Overall (n = 24) |
|-----------------|------------------|----------------|-----------------|
| Age (years)     | 53.1 ± 9.4       | 57.4 ± 6.3     | 55.0 ± 8.2      |
| Gender          |                  |                |                 |
| Male            | 4 (30.8%)        | 3 (27.3%)      | 7 (29.2%)       |
| Female          | 9 (69.2%)        | 8 (72.7%)      | 17 (70.8%)      |
| Pathology       |                  |                |                 |
| Adenocarcinoma  | 11 (84.6%)       | 11 (100.0%)    | 22 (91.6%)      |
| Adenosquamous carcinoma | 1 (7.7%) | 0 (0) | 1 (4.2%) |
| Squamous carcinoma | 1 (7.7%) | 0 (0) | 1 (4.2%) |
| Smoking history |                  |                |                 |
| Never           | 11 (84.6%)       | 8 (72.7%)      | 19 (79.2%)      |
| Current/former  | 2 (15.4%)        | 3 (27.3%)      | 5 (20.8%)       |
| CNS metastases  |                  |                |                 |
| Absence         | 8 (61.5%)        | 9 (81.8%)      | 17 (70.8%)      |
| Presence        | 5 (38.5%)        | 2 (18.2%)      | 7 (29.2%)       |
| Liver metastases|                  |                |                 |
| Absence         | 12 (92.3%)       | 11 (100.0%)    | 23 (95.8%)      |
| Presence        | 1 (7.7%)         | 0 (0)          | 1 (4.2%)        |
| NGS specimen    |                  |                |                 |
| Tumor tissue    | 12 (92.3%)       | 10 (90.9%)     | 22 (91.7%)      |
| Plasma          | 1 (7.7%)         | 1 (9.1%)       | 2 (8.3%)        |
| TP53 mutation   |                  |                |                 |
| None            | 3 (23.1%)        | 1 (9.1%)       | 4 (16.7%)       |
| Yes             | 2 (15.4%)        | 6 (54.5%)      | 8 (33.3%)       |
| NA              | 8 (61.5%)        | 4 (36.4%)      | 12 (50.0%)      |

FQEA, A763_Y764insFQEA; GY, D770delinsGY; NA, not available.

†There were no differences among the subgroups.

Results

Patient characteristics

As the flow chart showed (Supplementary Figure), 35 and 24 eligible patients who had received diverse EGFR TKIs as first- or second-line therapy were respectively included. In terms of first-line targeted therapy, 48.6% (n = 17) were females, 57.1% (n = 20) were never-smokers, 94.3% (n = 33) were lung adenocarcinomas, and 22.9% (n = 8) presented with baseline central nervous system (CNS) metastases. Nearly all of the patients (n = 34, 97.1%) received NGS testing via tumor tissues. The molecular findings revealed that 22.9% (n = 8) harbored ex20ins of A763_Y764insFQEA, 11.4% (n = 4) with D770delinsGY, 25.7% (n = 9) with D770_N771insSVD, 20.0% (n = 7) with V769_D770insASV, and the others (20.0%, n = 7) carried less common ex20ins variants including P772_H773insGHP, D770_N771insGD, N771_P772insH, P772_H773insH, H773_V774insAH, and H773delinsRY. Baseline clinicopathological characteristics of EGFR ex20ins patients with the first-line therapy are demonstrated in Table 1. Similarly, second-line targeted therapy data are listed in the Supplementary Table.

Efficacy

The cutoff time of this study was 15 October 2021, with a median follow-up of 24.0 months (95% CI, 19.49–28.51 months). All 35 patients had PFS events in the first-line setting, and 22 patients (91.7%) had PFS events in the second-line setting. In the first-line setting, among seven patients harboring V769_D770insASV, 4 showed de novo resistance to 1st- or 2nd-gen EGFR TKIs. Another two patients showed SD, with PFS of 5.6 and 7.7 months, and one case revealed SD but with a much longer PFS (35.9 months) to afatinib. Nine patients carried
D770_N771insSVD and 6 of them showed primary drug resistance to 1st- or 3rd-gen EGFR TKIs. Another three cases all revealed SD, with PFS ranging between 3.8 and 5.8 months. The overall ORR, DCR, and median PFS (mPFS) was 0 (0/16), 50.0% (8/16), and 2.07 months (95%CI, 0–6.25) for patients with V769_D770insASV and D770_N771insSVD (ASV/SVD) mutants.

A total of 12 patients were identified to be A763_Y764insFQEA and D770delinsGY mutants (FQEA/GY). Among 8 patients with A763_Y764insFQEA, only one showed de novo resistance to 1st-gen EGFR TKI (icotinib). Two patients showed PR, including one with afatinib (PFS, 24 months) and one with osimertinib (PFS, 3.1 months). The other 5 patients all kept SD from 1st- or 3rd-gen EGFR TKIs, with PFS ranging between 3.4 and 15.3 months. Among four patients with D770delinsGY, two showed PR and one showed SD to osimertinib, with PFS of 5.1 and 18.2 months. Only one case revealed de novo resistance to 3rd-gen EGFR TKI (almonertinib). The overall ORR, DCR, and mPFS for patients carrying FQEA/GY mutants were 33.3% (4/12), 83.3% (10/12), and 9.97 months (95%CI, 4.75–15.19).

In addition, 7 patients harbored other less common ex20ins subtypes, including P772_H773insGHP (n = 1), D770_N771insGD (n = 1), N771_P772insH (n = 1), P772_H773insH (n = 2), H773_V774insAH (n = 1), and H773delinsRY (n = 1), and the respective ORR, DCR, and mPFS were 0 (0/7), 42.9% (3/7), and 2.03 months (95%CI, 0–4.86) for them receiving 1st-to-3rd-gen EGFR TKIs. It was observed significant mPFS difference between subgroup FQEA/GY vs. ASV/SVD mutants (9.97 vs.2.07 months, HR = 0.33, 95% CI, 0.13–0.85, p = 0.02), and FQEA/GY vs. other insertion mutants (9.97 vs.2.03 months, HR = 0.26, 95%CI, 0.08–0.78, p = 0.006). No difference on mPFS was observed between subgroup ASV/SVD and other insertion mutants (2.07 vs.2.03 months, HR = 0.80, 95%CI, 0.32–1.98, p = 0.70).

The PFS on the abovementioned three insertion subgroups was listed in Figure 1A. The targeted activity of EGFR TKIs for NSCLC patients with diverse ex20ins variants in the first-line setting was presented in Table 2.

In the second-line setting, seven patients were detected to be A763_Y764insFQEA. Among them, 3 showed PR and 4 revealed SD to 2nd- or 3rd-gen EGFR TKIs, with PFS outcomes between 4.8 and 30.2 months. Among six patients harboring D770delinsGY, one showed de novo resistance to afatinib (PFS, 0.6 months). Two patients showed PR, and 3 showed SD to 2nd- or 3rd-gen EGFR TKIs (afatinib, dacomitinib, osimertinib), with PFS between 4.1 and 7.3 months. The ORR, DCR, and mPFS were 38.5% (5/13), 92.3% (12/13), and 6.77 months (95%CI, 5.48–8.06) for patients with FQEA/GY mutants. In addition, only a total of 6 patients harbored ASV/SVD mutants and showed short PFS (1.0–5.5 months) and no response treated with 2nd- or 3rd-gen EGFR TKIs. In addition, 5 patients harbored other ex20ins subtypes (3 of H773_V774insNPH, one of H773_V774insPH, and one of N771delinsNPHVC). Among these non-FQEA/GY patients, the ORR, DCR, and mPFS were 9.1% (1/11), 63.6% (7/11), and 2.23 months (95%CI, 1.19–3.28), respectively. The mPFS of patients harboring FQEA/GY mutants was significantly longer compared with those with other insertions (6.77 vs.2.23 months, HR = 0.14, 95%CI, 0.04–0.46, p < 0.001) (Figure 1B).

**Molecular structures and binding activity to EGFR TKIs**

On the 3D-based structure of the A763_Y764insFQEA variant, although the conformation was slightly altered by the insertion of four amino acids Phe-Gln-Glu-Ala within the C-helix (marked in red in Figure 2A), the overall protein structure of EGFR keeps stable and the binding affinity of...
small molecules is not affected. It is observed that there is a certain distance around the binding pocket (marked in pink) of the small molecule (marked in green) and the inserted FQEA sequence (marked in brown), indicating no direct effect on the binding of EGFR inhibitors (Figure 2A). The 2nd-gen TKI afatinib (Figure 2B) and dacomitinib (Figure 2C) both reveal the most favorable binding affinity to A763_Y764insFQEA mutant by the interaction of H-bonds between N of quinazoline-Met793 and Carbonyl-Cys797, along with salt-bridge between Amine-Asp800, the covalent bond between Michael acceptor-Cys797, and hydrophobic interaction with 3-chloro-4-fluorophenyl. By comparison, 3rd-gen TKI osimertinib (Figure 2D), and novel anti-ex20ins inhibitors mobocertinib (Figure 2F) and CLN-081 (Figure 2G) bind to A763_Y764insFQEA mutant with less potency, interacting with H-bond between N of pyrimidine-

| Exon 20 insertion variant | TKI      | Best response | PFS (months) | Ongoing treatment |
|---------------------------|----------|---------------|--------------|-------------------|
| FQEA/GY (n = 12)          | Icotinib | PD            | 1.0          | No                |
| A763_Y764insFQEA          | Osimertinib | PR        | 3.1          | Yes               |
| A763_Y764insFQEA          | Osimertinib | SD        | 3.4          | Yes               |
| A763_Y764insFQEA          | Osimertinib | SD        | 5.2          | Yes               |
| A763_Y764insFQEA          | Dacomitinib | SD        | 6.8          | Yes               |
| A763_Y764insFQEA          | Osimertinib | SD        | 7.8          | No                |
| A763_Y764insFQEA          | Gefitinib | SD          | 15.3         | No                |
| A763_Y764insFQEA          | Afatinib | PR          | 24.0         | Yes               |
| D770delinsGY              | Almonertinib | PD    | 1.7          | No                |
| D770delinsGY              | Osimertinib | PR        | 5.1          | No                |
| D770delinsGY              | Osimertinib | SD        | 10.0         | No                |
| D770delinsGY              | Osimertinib | PR        | 18.2         | Yes               |
| ASV/SVD (n = 16)          | Erlotinib | PD          | 0.9          | No                |
| V769_D770insASV            | Gefitinib | PD          | 1.0          | No                |
| V769_D770insASV            | Gefitinib | PD          | 1.2          | No                |
| V769_D770insASV            | Gefitinib | PD          | 1.7          | No                |
| V769_D770insASV            | Gefitinib | SD          | 5.6          | No                |
| V769_D770insASV            | Osimertinib | SD    | 7.7          | No                |
| V769_D770insASV            | Afatinib | SD          | 35.9         | No                |
| D770_N771insSVD            | Gefitinib | PD          | 0.8          | No                |
| D770_N771insSVD            | Osimertinib | PD        | 0.8          | No                |
| D770_N771insSVD            | Gefitinib | PD          | 1.0          | No                |
| D770_N771insSVD            | Gefitinib | PD          | 1.3          | No                |
| D770_N771insSVD            | Osimertinib | SD        | 3.8          | No                |
| D770_N771insSVD            | Afatinib | SD          | 5.4          | No                |
| D770_N771insSVD            | Osimertinib | SD    | 5.8          | No                |
| D770_N771insSVD            | Osimertinib | SD        | 6.2          | No                |
| D770_N771insSVD            | Osimertinib | SD    | 12.2         | No                |
| Other insertions (n = 7)   | Osimertinib | PD          | 0.7          | No                |
| P772_H773insH              | Gefitinib | PD          | 0.8          | No                |
| P772_H773insGHP            | Gefitinib | PD          | 0.9          | No                |
| H773delinsRY               | Osimertinib | PD        | 2.0          | No                |
| D770_N771insGD             | Afatinib | SD          | 4.6          | No                |
| N771_P772insH              | Osimertinib | SD    | 7.8          | No                |
| P772_H773insH              | Afatinib | SD          | 8.7          | No                |

PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease; TKI, tyrosine kinase inhibitor.
Met793 and covalent bond between Michael acceptor-Cys797. In addition, poziotinib also interacts better with A763_Y764insFQEA confirmation by H-bond between N of pyrimidine-Met793, the covalent bond between Michael acceptor-Cys797 and hydrophobic interaction with 2-fluoro-3-chloro-4- fluorophenyl (Figure 2E).

Similarly, the insertion of two amino acids Gly-Tyr (GY) at codon D770 after the C-helix (marked in red in Figure 3A) as well mildly altered the conformation, but the overall protein structure of EGFR has not been affected, with the binding affinity of small molecules not affected. It is also observed that the binding pocket (marked in pink) of the small molecule (marked in green) is near
TABLE 3 Binding free energy (kcal/mol) of different EGFR inhibitors for A763_Y764insFQEA and D770delinsGY insertions.

| EGFR inhibitor | A763_Y764insFQEA | D770delinsGY |
|---------------|------------------|--------------|
|               | GlideScore       | MM/GBSA      | GlideScore       | MM/GBSA      |
| Afatinib      | −9.177           | −88.75       | −9.524           | −97.02       |
| Dacomitinib   | −9.088           | −86.21       | −9.121           | −89.67       |
| Osimertinib   | −8.082           | −83.28       | −8.786           | −89.69       |
| Poziotinib    | −8.418           | −96.37       | −8.896           | −96.38       |
| Mobocertinib  | −8.280           | −81.84       | −7.188           | −85.27       |
| CLN-081       | −7.916           | −72.86       | −7.067           | −69.06       |

MM/GBSA, Molecular Mechanics/Generalized Born Surface Area.

Discussion

In this study, we provided comprehensive evidence for the targeted response of diverse EGFR TKIs among heterogeneous ex20ins EGFR mutants to diverse EGFR TKIs in a real-world NSCLC cohort, along with structural insights into the binding modes and binding activities of the A763_Y764insFQEA and D770delinsGY variants in particular. Our study is currently the largest in terms of the sample size that analyzes the response of ex20ins subtypes A763_Y764insFQEA and D770delinsGY to EGFR TKIs.

D770_N771insSVD and V769_D770insASV are the most common ex20ins mutants that are intrinsically resistant to 1st- to 3rd-gen EGFR TKIs (Naidoo et al., 2015; Riess et al., 2018; Yang et al., 2020; Yang G et al., 2021). Consistent with this, we did not observe any difference in the PFS of patients harboring ASV/ SVD insertions and those with other variants (median, 2.07 vs 2.03 months, HR = 0.80, p = 0.70) following EGFR-TKIs as the first-line treatment. The currently approved 1st- to 3rd-gen EGFR TKIs have overall limited activity against ex20ins variants of EGFR, with general ORRs of 8.7%–11%, and PFS ranging between 2.4 and 2.7 months (Yasuda, et al., 2012; Yasuda et al., 2013; Beau-Faller et al., 2014; Naidoo et al., 2015; Chen et al., 2016; Kuiper et al., 2016; Kosaka et al., 2017; Tu et al., 2017; Byeon et al., 2019; Hasegawa et al., 2019). Our previous study on nationwide data also indicated an ORR of 8.7%, and a shorter mPFS of 2.9 months for patients with EGFR ex20ins (Yang et al., 2020) in response to EGFR TKIs as first-line therapy. The patients who received 1st-gen EGFR TKIs in the first-line setting showed no response, with a mPFS of only 2.0 months (Yang et al., 2020).

In addition, we observed a more improved ORR (33.3% vs 0) and significant PFS benefit (median, 9.97 vs 2.07 months, HR = 0.33, p = 0.02) in patients harboring FQEA/GY mutants compared to those with ASV/SVD treated with 1st-to-3rd-gen EGFR TKIs as the first-line therapy. Similarly, an improved ORR (38.5% vs. 9.1%) and significant PFS benefit (median, 6.77 vs. 2.23 months, HR = 0.14, p < 0.001) were observed in patients with FQEA/GY mutants compared with those harboring other insertions in a second-line setting. The A763_Y764insFQEA variant is generally considered to be a specific ex20ins subtype to be sensitive to EGFR TKIs (Arcila et al., 2013; Voon et al., 2013; Yasuda et al., 2013; Hasegawa et al., 2019). In our previous study, two patients carrying A763_Y764insFQEA obtained reasonable PFS benefits when treated with afatinib (PFS of 8.2 months) and erlotinib (PFS of 14.3 months) (Yang et al., 2020). In another study by our group, the mPFS of NSCLC patients with EGFR ex20ins treated with osimertinib was 2.3 months. The mPFS of patients with FQEA/GY insertion was longer than those with other variants (4.2 vs. 2.2 months, p = 0.164), and half of the FQEA/GY patients showed PR to osimertinib (Yang G et al., 2021). Taken together, the A763_Y764insFQEA and D770delinsGY variants might be
more responsive to the currently approved EGFR TKIs compared to the other ex20ins subtypes, and they should be classified as such in the clinical setting.

Yasuda et al. (2013) established A763_Y764insFQEA as an EGFR TKI-sensitizing insertion and showed that the insertion of FQEA shifted the C-helix and altered the length of the β3-αC loop leading to an I759A replacement, which resulted in catalytic activation. Kosaka et al. (2017) generated Ba/F3 cells expressing D770delinsGY-mutant EGFR and found that this recombinant cell line was significantly more sensitive to dacomitinib compared to the other ex20ins Ba/F3 cell lines (p = 0.013). In addition, the D770delinsGY-expressing cells were slightly more sensitive to afatinib while other ex20ins conferred resistance to neratinib. Jänne et al. (2011) reported the case of one NSCLC patient with D770delinsGY who achieved a dramatic and sustained response to dacomitinib. Subsequently, Kosaka et al. (2017) demonstrated that the presence of glycine at codon 770 in D770delinsGY restored the sensitivity to TKIs, either by removing the steric hindrance imposed by D770, or by simply increasing the flexibility of the inserted loop. However, these initial studies did not evaluate the impact of these two specific insertions on the structure of EGFR and their binding affinities to diverse EGFR TKIs. In this study, we first constructed in silico structures of A763_Y764insFQEA and D770delinsGY and found that neither insertion alters the overall EGFR protein structure and drug binding pocket. The binding pocket was still located at a certain distance from the inserted FQEA or GY sequence and therefore did not exert any steric effect on the binding to EGFR TKIs. In addition, FQEA/GY mutants were most responsive and showed optimum binding to the 2nd-gen TKIs afatinib and dacomitinib.

Recently, the EGFR/MET-bispecific monoclonal antibody amivantamab was approved by the Food and Drug Administration (FDA) for NSCLC patients with EGFR ex20ins, based on an ORR of 40% and a mPFS of 8.3 months (Park et al., 2021). In addition, other newly designed EGFR kinase inhibitors including CLN-081, mobocertinib, and sunvozertinib (DZD9008) have also demonstrated selectivity against EGFR ex20ins (Piotrowska et al., 2021; Prelaj et al., 2021; Riely et al., 2021; Wang et al., 2022). Mobocertinib received FDA approval for NSCLC patients harboring EGFR ex20ins who had progressed following platinum-based chemotherapy, based on an ORR of 28% and a mPFS of 7.3 months (Zhou et al., 2021). A recent study on poziotinib revealed a confirmed ORR of 32% and a mPFS of 5.5 months in NSCLC patients with EGFR ex20ins (Elamin et al., 2022). Furthermore, the sensitivity to poziotinib was highly dependent on the insertion location. The near-loop insertions (amino acids A767-P772) were associated with a greater sensitivity compared to the far-loop insertions (H773-C775), with respective ORRs of 46% and 0% observed in near vs. far-loop, respectively (Elamin et al., 2022). The blueprint of precision-targeted therapy for NSCLC patients harboring the

![Figure 4](https://via.placeholder.com/150)

**FIGURE 4**
Currently approved or newly designed EGFR inhibitors against EGFR classic mutations, uncommon alterations, and exon 20 insertions.
classic mutations, uncommon alterations, and ex20ins in EGFR is shown in Figure 4. Several targeted inhibitors of EGFR ex20ins variants are currently in development and are expected to improve the therapeutic outcomes in NSCLC patients.

Although we have comprehensively analyzed the clinical activity of the currently approved EGFR TKIs for the specific EGFR ex20ins variants A763_Y764insFQEA and D770delinsGY in advanced NSCLC patients and provided evidence from structural and molecular dynamics simulation, several limitations must be noted. First, the retrospective nature of the real-world study likely introduced selection bias. In addition, although patients with FQEA/GY insertions represented the largest group in our cohort, their number was still small, which limits the reliability of the results regarding the clinical efficacy of the EGFR TKIs. Finally, although we explained the potential mechanism with respect to the binding affinity of the ex20ins variants, the structural modeling, and computational simulation will have to be validated by studies on cell lines and patient-derived xenograft models.

In conclusion, NSCLC patients harboring the A763_Y764insFQEA and D770delinsGY ex20ins variants of EGFR display a favorable response to currently approved EGFR TKIs, which should be classified according to the ex20ins variants for more effective therapeutic responses.

Data availability statement

Data supporting the results presented in this study are available from the corresponding author upon reasonable request.

Ethics statement

As an observational study, this research was exempted from obtaining patients’ informed consent without therapeutic intervention, and this research was approved by the Research Ethics Board of Cancer Hospital and conducted in accordance with the Declaration of Helsinki as well.

References

Arcila, M. E., Nafa, K., Chabot, J. E., Rekhtman, N., Lau, C., Reva, B. A., et al. (2013). EGFR exon 20 insertion mutations in lung adenocarcinomas: Prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol. Cancer Ther. 12, 220–229. doi:10.1158/1535-7163.mct-12-0620

Beau-Faller, M., Prim, N., Ruppert, A. M., Nanni-Metéllus, I., Lacave, R., Lacroix, L., et al. (2014). Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer in 10 117 patients: A multicentre observational study by the French ERMETIC-IFCT network. Ann. Oncol. 25, 126–131. doi:10.1093/annonc/mdt418

Byeon, S., Kim, Y., Lim, S. W., Cho, J. H., Park, S., Lee, J., et al. (2019). Clinical outcomes of EGFR exon 20 insertion mutations in advanced non-small cell lung cancer in korea. Cancer Res. Treat. 51, 623–631. doi:10.4143/crt.2018.151

Chen, D., Song, Z., and Cheng, G. (2016). Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations. Onco. Targets. Ther. 9, 4181–4186. doi:10.2147/OTT.S108242

Eck, M. J., and Yun, C. H. (2010). Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer. Biochim. Biophys. Acta 1804, 559–566. doi:10.1016/j.bbapap.2009.12.010

Elamin, Y. Y., Robichaux, J. P., Carter, B. W., Altan, M., Tran, H., Gibbons, D. L., et al. (2022). Pocetinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell 40, 754–767. e6. doi:10.1016/j.ccell.2022.06.006

Geng, D., Guo, Q., Huang, S., Zhang, H., Guo, S., and Li, X. (2022). Clinical and molecular characteristics of epidermal growth factor receptor exon 20 insertion

Author contributions

GY and YY designed the study, analyzed the collected data, and wrote the manuscript. JH constructed the mutant models and performed dynamics simulations. HX and SZ led the project. YY revised the manuscript. All authors have reviewed and approved the final version of this article.

Acknowledgments

The authors appreciate the linguistic assistance provided by TopEdit (www.topeditsci.com) during the preparation of this manuscript.

Conflict of interest

Author JH is employed by PharmaBlock Sciences (Nanjing) Inc.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.984503/full#supplementary-material
mutations in non-small-cell lung cancer. Clin. Transl. Oncol. 24, 379–387. doi:10.1007/s12091-021-02701-x

Hasegawa, H., Yasuda, H., Hamamoto, J., Masuzawa, K., Tani, T., Nukaga, S., et al. (2019). Efficacy of alatitinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations. Lung Cancer 127, 146–152. doi:10.1016/j.lungcan.2018.11.039

Janne, P. A., Boss, D. S., Camidge, D. R., Britten, C. D., Engelman, J. A., Garon, E. B., et al. (2011). Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin. Cancer Res. 17, 1131–1139. doi:10.1158/1078-0432.CCR-10-1220

Kosaka, T., Tanizaki, J., Paranal, R. M., Endoh, H., Lydon, C., Capelletti, M., et al. (2017). Response heterogeneity of EGFR and HER2 exon 20 insertions to covalent EGFR and HER2 inhibitors. Cancer Res. 77, 2712–2721. doi:10.1158/0008-5472.CAN-16-3404

Kuiper, J. L., Hashemi, S. M., Thunnissen, E., Snijders, P. J., Grünberg, K., Bloemena, E., et al. (2016). Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment. Br. J. Cancer 115, 1504–1512. doi:10.1038/bjc.2016.372

Lee, Y., Kim, T. M., Kim, D. W., Kim, S., Keam, B., et al. (2019). Preclinical modeling of osimertinib with NSCLC for EGFR exon 20 insertion mutations. J. Thorac. Oncol. 14, 1556–1566. doi:10.1016/j.jto.2019.05.006

Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H., Chu, D. T., Sajio, N., et al. (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947–957. doi:10.1056/NEJMoa0910699

Naido, J., Sima, C. S., Rodriguez, K., Bushy, N., Nafa, K., Ladanyi, M., et al. (2015). Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib. Cancer 121, 3212–3220. doi:10.1002/cncr.29493

Ozand, G. R., Lo, P. C., Nishino, M., Dahlberg, S. E., Lindeman, N. I., Butaney, M., et al. (2013). Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J. Thorac. Oncol. 8, 179–184. doi:10.1097/TO.0b013e18279f1a18

Park, K., Haura, E. B., Leighl, N. B., Mitchell, P., Shu, C. H., Girard, N., et al. (2021). Activity and safety of mobocertinib (TAK-788) in previously treated non-small-cell lung cancer harbouring uncommon EGFR mutations: A combined post-hoc analysis of LUX-lung 2, LUX-lung 3, and LUX-lung 6. Lancet. Oncol. 22, 1676–1689. doi:10.1016/S1470-2045(21)00165-5

Wu, J. Y., Wu, S. G., Yang, C. H., Gao, C. H., Chang, Y. L., Yu, C. J., et al. (2008). Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin. Cancer Res. 14, 4877–4882. doi:10.1158/1078-0432.CCR-07-5123

Yang, G. J., Li, J., Xu, H. Y., Sun, Y., Liu, L., Li, H. S., et al. (2021). Osimertinib for Chinese advanced non-small-cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations. Lung Cancer 152, 39–48. doi:10.1016/j.lungcan.2020.11.027

Yang, G., Li, J., Xu, H., Yang, Y., Yang, L., Xu, F., et al. (2020). EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study. Lung Cancer 145, 186–194. doi:10.1016/j.lungcan.2020.03.014

Yang, J. C.-H., Wang, M., Mitchell, P., Fang, J., Nian, W., Chiu, C.-H., et al. (2021). Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations. J. Oncol. 39, 9008. doi:10.1200/JCO.2021.39.15_suppl.9008

Yam, J. C., Sequist, L. V., Geater, S. L., Tsai, C. M., Mok, T. S., Schuler, M., et al. (2015). Clinical activity of alatitinib in patients with advanced non-small-cell lung cancer harbouiring uncommon EGFR mutations: A combined post-hoc analysis of LUX-lung 2, LUX-lung 3, and LUX-lung 6. Lancet Oncol. 16, 830–838. doi:10.1016/S1470-2045(15)00026-1

Yasuda, H., Kobayashi, S., and Costa, D. B. (2012). EGFR exon 20 insertion mutations in non-small-cell lung cancer: Preclinical data and clinical implications. Lancet. Oncol. 13, e23–e31. doi:10.1016/S1470-2045(11)70129-2

Yasuda, H., Park, E., Yun, C. H., Sing, N. J., Lucena-Araujo, A. R., Yeo, W. L., et al. (2013). Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci. Transl. Med. 5, 216ra177. doi:10.1126/scitranslmed.3007205

Zhou, C., Ramalingam, S. S., Kim, T. M., Kim, S. W., Yang, J. C., Riely, G. J., et al. (2021). Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: A phase 1/2 open-label nonrandomized clinical trial. JAMA Oncol. 7, e214761. doi:10.1001/jamaoncol.2021.4761